BSX · 10-Q · 2026Q2 · Full report

Acquisition / Partnership / Divestiture

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 75 · Surprise 60 · In source text

Boston Scientific agreed on January 15, 2026 to acquire 100% of Penumbra for approximately $14.5 billion, or $374 per share. Penumbra stockholders approved the transaction on May 6, 2026, but the companies received an FTC Second Request on March 16 and expect closing in the second half of 2026 subject to regulatory clearances. The company expects to fund approximately $11.0 billion of consideration with newly issued debt and cash, with the balance paid in Boston Scientific shares. Penumbra’s thrombectomy business will be integrated into the Cardiovascular division, and first-half 2026 investing cash flows also included $718 million for acquisitions and $1.501 billion of investments and technology acquisitions, primarily involving Nalu Medical and MiRus.

Key facts

• Boston Scientific announced on January 15, 2026 a definitive agreement to acquire 100% of Penumbra for $374 per share, or approximately $14.500 billion, with the transaction expected to be completed in the second half of 2026 subject to customary closing conditions including regulatory clearances. source
• During the first six months of 2026, investing activities included net cash payments of $718 million for acquisitions of multiple businesses primarily related to Nalu Medical, Inc.; net payments for investments and acquisitions of certain technologies of $1.501 billion primarily related to MiRus LLC; and purchases of property, plant and equipment and internal use software of $372 million. source

Impact estimates